Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Eugen F Mesaros, Gregory R Ott & Bruce D Dorsey. (2014) Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review. Expert Opinion on Therapeutic Patents 24:4, pages 417-442.
Read now
Read now
Anna Kruczynski, Georges Delsol, Camille Laurent, Pierre Brousset & Laurence Lamant. (2012) Anaplastic lymphoma kinase as a therapeutic target. Expert Opinion on Therapeutic Targets 16:11, pages 1127-1138.
Read now
Read now
Articles from other publishers (15)
Xiaoxia Liang, Pan Wu, Qian Yang, Yunyu Xie, Changliang He, Lizi Yin, Zhongqiong Yin, Guizhou Yue, Yuanfeng Zou, Lixia Li, Xu Song, Cheng Lv, Wei Zhang & Bo Jing. (2021) An update of new small-molecule anticancer drugs approved from 2015 to 2020. European Journal of Medicinal Chemistry 220, pages 113473.
Crossref
Crossref
Xiaoxia Liang, Qian Yang, Pan Wu, Changliang He, Lizi Yin, Funeng Xu, Zhongqiong Yin, Guizhou Yue, Yuanfeng Zou, Lixia Li, Xu Song, Cheng Lv, Wei Zhang & Bo Jing. (2021) The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020. Bioorganic Chemistry 113, pages 105011.
Crossref
Crossref
Christel A.S. Bergström, William N. Charman & Christopher J.H. Porter. (2016) Computational prediction of formulation strategies for beyond-rule-of-5 compounds. Advanced Drug Delivery Reviews 101, pages 6-21.
Crossref
Crossref
M.C. Boutterin, P. Mazot, C. Faure, S. Doly, N. Gervasi, M.L. Tremblay & M. Vigny. (2013) Control of ALK (wild type and mutated forms) phosphorylation: Specific role of the phosphatase PTP1B. Cellular Signalling 25:6, pages 1505-1513.
Crossref
Crossref
Cindy L O'Bryant, Sarah D Wenger, Miryoung Kim & Lisa A Thompson. (2013)
Crizotinib: A New Treatment Option for
ALK
-Positive Non-Small Cell Lung Cancer
. Annals of Pharmacotherapy 47:2, pages 189-197.
Crossref
Crossref
Simon Giroux. (2013) Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF. Bioorganic & Medicinal Chemistry Letters 23:2, pages 394-401.
Crossref
Crossref
Sandrine Vendeville & Maxwell D. Cummings. 2013.
371
386
.
Luca Mologni & Carlo Gambacorti-Passerini. (2012) New developments in the treatment of ALK-driven malignancies. Clinical Investigation 2:8, pages 835-852.
Crossref
Crossref
Diane E. Gingrich, Joseph G. Lisko, Matthew A. Curry, Mangeng Cheng, Matthew Quail, Lihui Lu, Weihua Wan, Mark S. Albom, Thelma S. Angeles, Lisa D. Aimone, R. Curtis Haltiwanger, Kevin Wells-Knecht, Gregory R. Ott, Arup K. Ghose, Mark A. Ator, Bruce Ruggeri & Bruce D. Dorsey. (2012) Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase. Journal of Medicinal Chemistry 55:10, pages 4580-4593.
Crossref
Crossref
Floor A.M. Duijkers, José Gaal, Jules P.P. Meijerink, Pieter Admiraal, Rob Pieters, Ronald R. de Krijger & Max M. van Noesel. (2012) High Anaplastic Lymphoma Kinase Immunohistochemical Staining in Neuroblastoma and Ganglioneuroblastoma Is an Independent Predictor of Poor Outcome. The American Journal of Pathology 180:3, pages 1223-1231.
Crossref
Crossref
Henry J. Breslin, Brandon M. Lane, Gregory R. Ott, Arup K. Ghose, Thelma S. Angeles, Mark S. Albom, Mangeng Cheng, Weihua Wan, R. Curtis Haltiwanger, Kevin J. Wells-Knecht & Bruce D. Dorsey. (2011)
Design, Synthesis, and Anaplastic Lymphoma Kinase (ALK) Inhibitory Activity for a Novel Series of 2,4,8,22-Tetraazatetracyclo[14.3.1.1
3,7
.1
9,13
]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene Macrocycles
. Journal of Medicinal Chemistry 55:1, pages 449-464.
Crossref
Crossref
Eugen F. Mesaros, Tho V. Thieu, Gregory J. Wells, Craig A. Zificsak, Jason C. Wagner, Henry J. Breslin, Rabindranath Tripathy, James L. Diebold, Robert J. McHugh, Ashley T. Wohler, Matthew R. Quail, Weihua Wan, Lihui Lu, Zeqi Huang, Mark S. Albom, Thelma S. Angeles, Kevin J. Wells-Knecht, Lisa D. Aimone, Mangeng Cheng, Mark A. Ator, Gregory R. Ott & Bruce D. Dorsey. (2011)
Strategies to Mitigate the Bioactivation of 2-Anilino-7-Aryl-Pyrrolo[2,1-
f
][1,2,4]triazines: Identification of Orally Bioavailable, Efficacious ALK Inhibitors
. Journal of Medicinal Chemistry 55:1, pages 115-125.
Crossref
Crossref
Veena R. Ganeshan & Nina F. Schor. (2011) Pharmacologic Management of High-Risk Neuroblastoma in Children. Pediatric Drugs 13:4, pages 245-255.
Crossref
Crossref
P. Jake Slavish, Jeanine E. Price, Qin Jiang, Xiaoli Cui, Stephan W. Morris & Thomas R. Webb. (2011) Synthesis of an aryloxy oxo pyrimidinone library that displays ALK-selective inhibition. Bioorganic & Medicinal Chemistry Letters 21:15, pages 4592-4596.
Crossref
Crossref
Craig A. Zificsak, Jay P. Theroff, Lisa D. Aimone, Thelma S. Angeles, Mark S. Albom, Mangeng Cheng, Eugen F. Mesaros, Gregory R. Ott, Matthew R. Quail, Ted L. Underiner, Weihua Wan & Bruce D. Dorsey. (2011) Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors. Bioorganic & Medicinal Chemistry Letters 21:13, pages 3877-3880.
Crossref
Crossref